With Novo Nordisk continuing to break sales records with its obesity and diabetes drugs Wegovy and Ozempic, investment in weight loss drug development shows no signs of slowing up. Boston-based biotech Kailera Therapeutics is the latest player to enter the arena, emerging with a whopping $400 million Series A funding round to advance a portfolio of therapies for “obesity and related conditions.”

Kailera is developing both injectable and oral treatments that have already shown promise in clinical-stage trials. The company’s pipeline has been exclusively licensed from Chinese pharma giant Jiangsu Hengrui Pharmaceuticals for global development and commercialization outside of China.

https://longevity.technology/news/kailera-emerges-with-400m-to-advance-next-generation-weight-loss-drugs/